Acyclovir and Hydrocortisone
Medically reviewed on Jan 25, 2019
(ay SYE kloe veer & hye droe KOR ti sone)
- Hydrocortisone and Acyclovir
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Xerese: Acyclovir 5% and hydrocortisone 1% (5 g) [contains cetostearyl alcohol, propylene glycol]
Brand Names: U.S.
- Antiviral Agent, Topical
- Corticosteroid, Topical
Acyclovir: Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.
Hydrocortisone: Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties.
Use: Labeled Indications
Herpes labialis: Treatment of recurrent herpes labialis (cold sores) in children ≥6 years and adults.
There are no contraindications listed in the manufacturer’s US labeling.
Canadian labeling:Known or suspected history of hypersensitivity to acyclovir, valacyclovir, hydrocortisone or any component of the cream.
Herpes labialis (cold sores): Topical: Apply 5 times/day for 5 days
Refer to adult dosing.
Herpes labialis (cold sores): Children ≥6 years and Adolescents: Topical: Apply 5 times daily for 5 days; initiate therapy at first sign of infection (ie, during the prodrome or when lesions appear)
For external use only; not for use in the eye, inside the mouth or nose, or on the genitals. Wash hands before and after application. Use sufficient amount to cover the affected area(s), including the outer margin of cold sore; do not rub affected area. Initiate therapy early (ie, during the prodrome or when lesions appear).
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze.
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination
Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Monitor therapy
Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. Monitor therapy
<1%, postmarketing, and/or case reports: Allergic contact sensitivity, application site reaction, burning sensation of skin, contact dermatitis (when applied under occlusion), dyschromia, erythema, exfoliation of skin, tingling of skin, xeroderma
Concerns related to adverse effects:
• Sensitization: Use has been associated with local sensitization (irritation).
• Herpes labialis: Appropriate use: Treatment should begin with the first signs or symptoms. For external use only to the lips and around the mouth; do not apply to eye, inside the mouth or nose, or on the genitals. Contact healthcare provider if cold sore does not heal in 2 weeks.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Immunocompromised patients: Use with caution in immunocompromised patients.
Pregnancy Risk Factor
Animal reproduction studies and studies in pregnant women have not been conducted with Xerese. Systemic exposure of acyclovir and hydrocortisone after topical administration is minimal. See individual agents.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience bad taste, dry skin, burning, skin tingling, or skin discoloration. Have patient report immediately to prescriber severe skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about acyclovir/hydrocortisone topical
- Acyclovir/hydrocortisone topical Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 3 Reviews
- Drug class: topical steroids with anti-infectives
- Acyclovir and hydrocortisone topical
- Acyclovir and Hydrocortisone
- Acyclovir and hydrocortisone Topical application (Advanced Reading)
Other brands: Xerese